Unilife

A company specializing in injectable drug delivery systems

Unilife Corporation was a company that specialized in the design, development, and manufacture of injectable drug delivery systems. The company was headquartered in King of Prussia, Pennsylvania, and it primarily served the pharmaceutical and biotechnology industries.

History

Unilife was founded in 2002 and initially focused on the development of safety syringes. Over the years, the company expanded its product offerings to include a wide range of injectable drug delivery systems. Unilife went public in 2010 and was listed on the NASDAQ stock exchange under the ticker symbol "UNIS."

In 2017, Unilife filed for Chapter 11 bankruptcy protection. The company's assets were subsequently acquired by Amgen, a leading biotechnology company.

Products

Unilife developed a variety of products designed to improve the safety and efficiency of drug delivery. These products included:

• Prefilled Syringes: Unilife's prefilled syringes were designed to enhance patient safety and compliance by reducing the risk of needlestick injuries and ensuring accurate dosing.

• Wearable Injectors: These devices were designed for the delivery of large-volume biologics and other medications that require extended infusion times.

• Auto-Injectors: Unilife's auto-injectors were designed to provide patients with a convenient and easy-to-use method for self-administration of medications.

• Ocular Delivery Systems: These systems were developed for the delivery of drugs to the eye, offering a targeted approach to treating ocular conditions.

Unilife Pharma Logo

Technology

Unilife's technology was centered around the development of innovative drug delivery systems that addressed the needs of both patients and healthcare providers. The company's products were designed to improve patient safety, enhance drug efficacy, and reduce healthcare costs.

Unilife's proprietary technologies included:

• Unifill: A platform of prefilled syringes that incorporated automatic needle retraction to prevent needlestick injuries.

• Uniflow: A technology designed for the delivery of viscous biologics through wearable injectors.

• Uniflex: A flexible delivery system for the administration of drugs to the eye.

Bankruptcy and Acquisition

In April 2017, Unilife filed for Chapter 11 bankruptcy protection due to financial difficulties. The company's assets were later acquired by Amgen, which integrated Unilife's technologies into its own drug delivery systems.

Related pages

• Pharmaceutical industry
• Biotechnology
• Drug delivery
• Medical device

A laboratory setting related to biotechnology